Effects of chronic quercetin treatment in experimental renovascular hypertension.
The aims of the present study were to analyse the effects of an oral daily dose (10 mg/kg) of the dietary flavonoid quercetin for five weeks in two-kidney, one-clip (2K1C) Goldblatt (GB) hypertensive rats. The evolution of systolic blood pressure was followed by weekly measurements, and morphological variables, proteinuria, plasma nitrates plus nitrites (NOx) and thiobarbituric acid reactive substances (TBARS), liver oxidative stress markers and endothelial function were determined at the end of the experimental period. Quercetin treatment reduced systolic blood pressure of GB rats, producing no effect in control animals. It also reduced cardiac hypertrophy and proteinuria developed in GB hypertensive rats. Decreased endothelium-dependent relaxation to acetylcholine of aortic rings from GB rats was improved by chronic quercetin treatment, as well as increased endothelium-dependent vasoconstrictor response to acetylcholine and overproduction of TXB2 by aortic vessels of GB rats, being without effect in normotensive animals. Increased plasma NOx and TBARS, and decreased liver total glutathione (GSH) levels and glutathione peroxidase (GPX) activity were observed in GB hypertensive rats compared to the control animals. Normalisation of plasma NOx and TBARS concentrations and improvement of the antioxidant defences system in liver accompanied the antihypertensive effect of quercetin. We conclude that chronic oral treatment with quercetin shows both antihypertensive and antioxidant effects in this model of renovascular hypertension.
García-Saura
María Francisca
MF
Department of Pharmacology, School of Pharmacy, University of Granada, Granada, Spain.
Galisteo
Milagros
M
Villar
Inmaculada Concepción
IC
Bermejo
Almudena
A
Zarzuelo
Antonio
A
Vargas
Félix
F
Duarte
Juan
J
D000818:Animals; D000975:Antioxidants / Q000378:metabolism; D001011:Aorta / Q000473:pathology; D001794:Blood Pressure; D001835:Body Weight; D004032:Diet; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000378:metabolism; D005978:Glutathione / Q000378:metabolism; D005979:Glutathione Peroxidase / Q000378:metabolism; D006978:Hypertension, Renovascular / Q000188:drug therapy*; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D009566:Nitrates / Q000097:blood; D009573:Nitrites / Q000097:blood; D009929:Organ Size; D018384:Oxidative Stress; D011189:Potassium Chloride / Q000494:pharmacology; D011507:Proteinuria / Q000378:metabolism; D011794:Quercetin / Q000378:metabolism / Q000494:pharmacology*; D051381:Rats; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D013929:Thromboxane B2 / Q000378:metabolism; D013997:Time Factors
D000975:Antioxidants; D009566:Nitrates; D009573:Nitrites; D017392:Thiobarbituric Acid Reactive Substances; D013929:Thromboxane B2; D011189:Potassium Chloride; D011794:Quercetin; D005979:Glutathione Peroxidase; D005978:Glutathione